FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385060586> ?p ?o ?g. }

• W4385060586 endingPage "4015" @default.
• W4385060586 startingPage "4004" @default.
• W4385060586 abstract "One of the main challenges of PET imaging with 89Zr-labeled monoclonal antibodies (mAbs) remains the long blood circulation of the radiolabeled mAbs, leading to high background signals, decreasing image quality. To overcome this limitation, here we report the use of a bioorthogonal linker cleavage approach (click-to-release chemistry) to selectively liberate [89Zr]Zr-DFO from trans-cyclooctene-functionalized trastuzumab (TCO-Tmab) in blood, following the administration of a tetrazine compound (trigger) in BT-474 tumor-bearing mice. Methods: We created a series of TCO-DFO constructs and evaluated their performance in [89Zr]Zr-DFO release from Tmab in vitro using different trigger compounds. The in vivo behavior of the best performing [89Zr]Zr-TCO-Tmab was studied in healthy mice first to determine the optimal dose of the trigger. To find the optimal time for the trigger administration, the rate of [89Zr]Zr-TCO-Tmab internalization was studied in BT-474 cancer cells. Finally, the trigger was administered 6 h or 24 h after [89Zr]Zr-TCO-Tmab- administration in tumor-bearing mice to liberate the [89Zr]Zr-DFO fragment. PET scans were obtained of tumor-bearing mice that received the trigger 6 h post-[89Zr]Zr-TCO-Tmab administration. Results: The [89Zr]Zr-TCO-Tmab and trigger pair with the best in vivo properties exhibited 83% release in 50% mouse plasma. In tumor-bearing mice the tumor-blood ratios were markedly increased from 1.0 ± 0.4 to 2.3 ± 0.6 (p = 0.0057) and from 2.5 ± 0.7 to 6.6 ± 0.9 (p < 0.0001) when the trigger was administered at 6 h and 24 h post-mAb, respectively. Same day PET imaging clearly showed uptake in the tumor combined with a strongly reduced background due to the fast clearance of the released [89Zr]Zr-DFO-containing fragment from the circulation through the kidneys. Conclusions: This is the first demonstration of the use of trans-cyclooctene-tetrazine click-to-release chemistry to release a radioactive chelator from a mAb in mice to increase tumor-to-blood ratios. Our results suggest that click-cleavable radioimmunoimaging may allow for substantially shorter intervals in PET imaging with full mAbs, reducing radiation doses and potentially even enabling same day imaging." @default.
• W4385060586 created "2023-07-23" @default.
• W4385060586 creator A5003950067 @default.
• W4385060586 creator A5017460653 @default.
• W4385060586 creator A5038198960 @default.
• W4385060586 creator A5043499229 @default.
• W4385060586 creator A5066985422 @default.
• W4385060586 creator A5072310621 @default.
• W4385060586 creator A5073118760 @default.
• W4385060586 creator A5081904946 @default.
• W4385060586 creator A5090631664 @default.
• W4385060586 date "2023-01-01" @default.
• W4385060586 modified "2023-10-14" @default.
• W4385060586 title "Click-to-Release: Cleavable Radioimmunoimaging with [⁸⁹Zr]Zr-DFO-<i>Trans</i>-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio" @default.
• W4385060586 cites W1492159527 @default.
• W4385060586 cites W1971234323 @default.
• W4385060586 cites W1974778911 @default.
• W4385060586 cites W1978407833 @default.
• W4385060586 cites W2009347818 @default.
• W4385060586 cites W2037983211 @default.
• W4385060586 cites W2038520392 @default.
• W4385060586 cites W2044465955 @default.
• W4385060586 cites W2065293903 @default.
• W4385060586 cites W2106974977 @default.
• W4385060586 cites W2111789849 @default.
• W4385060586 cites W2122767481 @default.
• W4385060586 cites W2141346487 @default.
• W4385060586 cites W2155314830 @default.
• W4385060586 cites W2179968303 @default.
• W4385060586 cites W2427310931 @default.
• W4385060586 cites W2510621441 @default.
• W4385060586 cites W2526827711 @default.
• W4385060586 cites W2620846126 @default.
• W4385060586 cites W2624259991 @default.
• W4385060586 cites W2652858501 @default.
• W4385060586 cites W2735333800 @default.
• W4385060586 cites W2737201964 @default.
• W4385060586 cites W2748772622 @default.
• W4385060586 cites W2772842275 @default.
• W4385060586 cites W2787623985 @default.
• W4385060586 cites W2788496061 @default.
• W4385060586 cites W2792441199 @default.
• W4385060586 cites W2800788936 @default.
• W4385060586 cites W2905067033 @default.
• W4385060586 cites W2910510051 @default.
• W4385060586 cites W2994597968 @default.
• W4385060586 cites W3012485477 @default.
• W4385060586 cites W3037832279 @default.
• W4385060586 cites W3094963677 @default.
• W4385060586 cites W3203983721 @default.
• W4385060586 doi "https://doi.org/10.7150/thno.84865" @default.
• W4385060586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37554267" @default.
• W4385060586 hasPublicationYear "2023" @default.
• W4385060586 type Work @default.
• W4385060586 citedByCount "0" @default.
• W4385060586 crossrefType "journal-article" @default.
• W4385060586 hasAuthorship W4385060586A5003950067 @default.
• W4385060586 hasAuthorship W4385060586A5017460653 @default.
• W4385060586 hasAuthorship W4385060586A5038198960 @default.
• W4385060586 hasAuthorship W4385060586A5043499229 @default.
• W4385060586 hasAuthorship W4385060586A5066985422 @default.
• W4385060586 hasAuthorship W4385060586A5072310621 @default.
• W4385060586 hasAuthorship W4385060586A5073118760 @default.
• W4385060586 hasAuthorship W4385060586A5081904946 @default.
• W4385060586 hasAuthorship W4385060586A5090631664 @default.
• W4385060586 hasBestOaLocation W43850605861 @default.
• W4385060586 hasConcept C121608353 @default.
• W4385060586 hasConcept C126322002 @default.
• W4385060586 hasConcept C150903083 @default.
• W4385060586 hasConcept C178790620 @default.
• W4385060586 hasConcept C185592680 @default.
• W4385060586 hasConcept C207001950 @default.
• W4385060586 hasConcept C21951064 @default.
• W4385060586 hasConcept C2778754187 @default.
• W4385060586 hasConcept C2779786085 @default.
• W4385060586 hasConcept C530470458 @default.
• W4385060586 hasConcept C69610077 @default.
• W4385060586 hasConcept C71924100 @default.
• W4385060586 hasConcept C86803240 @default.
• W4385060586 hasConcept C930959 @default.
• W4385060586 hasConceptScore W4385060586C121608353 @default.
• W4385060586 hasConceptScore W4385060586C126322002 @default.
• W4385060586 hasConceptScore W4385060586C150903083 @default.
• W4385060586 hasConceptScore W4385060586C178790620 @default.
• W4385060586 hasConceptScore W4385060586C185592680 @default.
• W4385060586 hasConceptScore W4385060586C207001950 @default.
• W4385060586 hasConceptScore W4385060586C21951064 @default.
• W4385060586 hasConceptScore W4385060586C2778754187 @default.
• W4385060586 hasConceptScore W4385060586C2779786085 @default.
• W4385060586 hasConceptScore W4385060586C530470458 @default.
• W4385060586 hasConceptScore W4385060586C69610077 @default.
• W4385060586 hasConceptScore W4385060586C71924100 @default.
• W4385060586 hasConceptScore W4385060586C86803240 @default.
• W4385060586 hasConceptScore W4385060586C930959 @default.
• W4385060586 hasIssue "12" @default.
• W4385060586 hasLocation W43850605861 @default.
• W4385060586 hasLocation W43850605862 @default.
• W4385060586 hasLocation W43850605863 @default.

• next